National Institute of Allergy and Infectious Diseases
  National Institutes of Health
NIAID Home Health & Science Research Funding Research News & Events Labs at NIAID About NIAID

News & Events
 News Releases
  2008
  2007
  2006
  2005
  2004
  2003
  2002
  2001
  2000
  1999
  1998
  1997
  1996
  1995
  By Topic
 Qs & As
 Media Inquiries
 Events & Calendars
 NIAID Discovery News
 Focus on Features
 NIAID in the News
 Resources


National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Monday, June 23, 2008

 


NIAID MEDIA AVAILABILITY
Study Further Defines Potential Role of Fish-Based Fatty Acids in Resolving, Preventing Asthma

WHAT:

In an ongoing effort to determine the anti-inflammatory value of diets rich in some types of fish, scientists studying asthma and allergic reactions have found that a molecule produced by the body from omega-3 fatty acids helps resolve and prevent respiratory distress in laboratory mice. The research, supported by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, was led by a research team at Brigham and Women’s Hospital and Harvard Medical School.

Resolvin E1 (RvE1) is a metabolic product of an omega-3 fatty acid found in cold-water fish such as salmon, mackerel and anchovies. It is made by the body in response to the onset of inflammation. This study identified RvE1 as having a key role in both dampening the development of airway inflammation and promoting its resolution in mice, in part by dampening innate immune signals that trigger inflammation. Other studies have indicated that increased levels of omega-3 fatty acids are associated with lower asthma prevalence in people, but the mechanisms to support that observation are poorly understood. This study provides scientists an opportunity to focus on the role of RvE1 as a potential therapeutic candidate.

ARTICLE:

O Haworth et al. Resolvin E1 regulates interleukin-23, interferon-y and lipoxin A4 to promote resolution of allergic airway inflammation. Nature Immunology DOI 10.1038/ni.1627

WHO:

Alkis Togias, M.D., Chief of the Asthma and Inflammation Section, NIAID Allergy and Inflammation Branch, is available to comment on this article.

CONTACT: To schedule interviews, contact the NIAID Office of Communications, 301-402-1663, niaidnews@niaid.nih.gov.


NIAID is a component of the National Institutes of Health. NIAID supports basic and applied research to prevent, diagnose and treat infectious diseases such as HIV/AIDS and other sexually transmitted infections, influenza, tuberculosis, malaria and illness from potential agents of bioterrorism. NIAID also supports research on basic immunology, transplantation and immune-related disorders, including autoimmune diseases, asthma and allergies.

The National Institutes of Health (NIH)—The Nation's Medical Research Agency—includes 27 Institutes and Centers and is a component of the U. S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov

###

 

back to top


See Also

Media Contact Info

News Releases by Topic


NIH Logo

The National Institute of Allergy and Infectious Diseases is a component of the National Institutes of Health, U.S. Department of Health and Human Services

NIAID Logo

Search in News & Events
 
Print Icon Print this page
E-mail Icon E-mail this page

See Also

Media Contact Info

News Releases by Topic